[1] ZHANG Q J,HAN B,LAN L,et al.High frequency of OTOF mutations in Chinese infants with congenital auditory neuropathy spectrum disorder[J].Clinical Genetics,2016,90(3):238-246.

[2] 韩磊，汤洪海，王大奇，等.OTOF基因突变听神经病的治疗进展[J].中国眼耳鼻喉科杂志，2023,23(2):117-122.

[3] FORLI F,CAPOBIANCO S,BERRETTINI S,et al.Temperature-sensitive auditory neuropathy:report of a novel variant of OTOF Gene and review of current literature[J].Medicina,2023,59(2):352.

[4] AKIL O,DYKA F,CALVET C,et al.Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model[J].ProcNatl Acad Sci USA,2019,116(10):4496-4501.

[5] LANDEGGER L D,PAN B,ASKEW C,et al.A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear[J].Nat Biotechnol,2017,35(3):280-284.

[6] AL-MOYED H,CEPEDA A P,JUNG S,et al.A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice[J].EMBO Mol Med,2019,11(1):e9396.

[7] ZHANG L,WANG H,XUN M,et al.Preclinical evaluation of the efficacy and safety of AAV1-hOTOF in mice and nonhuman primates[J].Mol Ther Methods ClinDev,2023,31:101154.

[8] TANG H,WANG H,WANG S,et al.Hearing of Otof-deficient mice restored by trans-splicing of N-and C-terminal otoferlin[J].Human Genetics,2023,142(2):289-304.

[9] WANG H,XUN M,TANG H,et al.Hair cell-specific Myo15 promoter-mediated gene therapy rescues hearing in DFNB9 mouse model[J].Mol Ther Nucleic Acids,2024,35(1):102135.

[10] HU S W,LV J,WANG Z,et al.Engineering of the AAV-compatible hair cell-specific small-size Myo15 promoter for Gene therapy in the inner ear[J].Research,2024,7:0341.

[11] RRG-003AAV治疗DFNB9先天性耳聋的安全性、耐受性及初步疗效研究[EB/OL].中国临床试验注册中心，(2022-09-01).https://www.chictr.org.cn/showproj.html?proj=194989.

[12] An Investigator Initiated Study for OTOV101N+OTOV101C Injection[EB/OL].ClinicalTrials.gov,(2023-5-9).https://classic.clinicaltrials.gov/show/NCT05901480.

[13] Gene Therapy Trial for Otoferlin Gene-Mediated Hearing Loss[EB/OL].ClinicalTrials.gov,(2023-2-8).https://classic.clinicaltrials.gov/show/NCT05821959.

[14] A Study of DB-OTO,an AAV Based Gene Therapy,in Children/Infants With Hearing Loss Due to Otoferlin Mutations (CHORD)[EB/OL].Clinical Trials.gov,(2023-3-15).https://classic.clinicaltrials.gov/show/NCT05788536.

[15] A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations (AUDIOGENE)[EB/OL].Clinical Trials Information System,(2023-7-18).https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-504466-28-00

[16] LV J,WANG H,CHENG X,et al.AAV1-hOTOF gene therapy for autosomal recessive deafness 9:a single-arm trial[J].The Lancet,2024.DOI:10.1016/S0140-6736(23)02874-X.

[17] WANG H,CHEN Y,LV J,et al.Bilateral gene therapy in children with autosomal recessive deafness 9:single-arm trial results[J].Nat Med,2024,30(7):1898-1904.

[18] QI J,ZHANG L,TAN F,et al.Preclinical efficacy and safety evaluation of AAV-OTOF in DFNB9 mouse model and nonhuman primate[J].Advanced Science,2024,11(3):2306201.

[19] QI J,TAN F,ZHANG L,et al.AAV-mediated gene therapy restores hearing in patients with DFNB9 deafness[J].Advanced Science,2024:2306788.

[20] ANDRES-MATEOS E,LANDEGGER L D,UNZU C,et al.Choice of vector and surgical approach enables efficient cochlear gene transfer in nonhuman primate[J].Nature Communications,2022,13(1):1359.

[21] VONA B,RAD A,REISINGER E.The many faces of DFNB9:relating OTOF variants to hearing impairment[J].Genes (Basel),2020,11(12):1411.

[22] WEI? C,ZIEGLER A,BECKER L L,et al.Gene replacement therapy with onasemnogeneabeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg:an observational cohort study[J].Lancet Child Adolesc Health,2022,6(1):17-27.

[23] FINKEL R S,CHIRIBOGA C A,VAJSAR J,et al.Treatment of infantile-onset spinal muscular atrophy with nusinersen:final report of a phase 2,open-label,multicentre,dose-escalation study[J].Lancet Child Adolesc Health,2021,5(7):491-500.

[24] DAY J W,FINKEL R S,CHIRIBOGA C A,et al.Onasemnogeneabeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE):an open-label,single-arm,multicentre,phase 3 trial[J].Lancet Neurol,2021,20(4):284-293.

[25] MERCURI E,VILCHEZ J J,BOESPFLUG-TANGUY O,et al.Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS):a multicentre,randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Neurol,2024,23(4):393-403.

[26] HOY S M.Delandistrogene moxeparvovec:first approval[J].Drugs,2023,83(14):1323-1329.

[27] RANGARAJAN S,WALSH L,LESTER W,et al.AAV5-factor VIII gene transfer in severe hemophilia A[J].N Engl J Med,2017,377(26):2519-2530.

[28] KOHN D B,BOOTH C,SHAW K L,et al.Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency[J].N Engl J Med,2021,384(21):2002-2013.

[29] FLANIGAN K M,VETTER T A,SIMMONS T R,et al.A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2[J].Mol Ther Methods Clin Dev,2022,27:47-60.

[30] 王秋菊.新医学时代遗传性聋研究与应用[J].听力学及言语疾病杂志，2023,31(3):197-201.

[31] 舒易来，范新泰，高子雯，等.遗传性耳聋基因治疗专家共识(2023,上海)[J].中国眼耳鼻喉科杂志，2024,24(1):1-6.

[32] NIST-LUND C A,PAN B,PATTERSON A,et al.Improved TMC1 gene therapy restores hearing and balance in mice with genetic inner ear disorders[J].Nat Commun,2019,10(1):236.

[33] WU J,SOLANES P,NIST-LUND C,et al.Single and dual vector gene therapy with AAV9-PHP.B rescues hearing in tmc1 mutant mice[J].Mol Ther,2021,29(3):973-988.

[34] YEH W H,SHUBINA-OLEINIK O,LEVY J M,et al.In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness[J].Sci Transl Med,2020,12(546):eaay9101.

[35] SHUBINA-OLEINIK O,NIST-LUND C,FRENCH C,et al.Dual-vector gene therapy restores cochlear amplification and auditory sensitivity in a mouse model of DFNB16 hearing loss[J].Sci Adv,2021,7(51):eabi7629.

[36] LENTZ J J,PAN B,PONNATH A,et al.Direct delivery of antisense oligonucleotides to the middle and inner ear improves hearing and balance in Usher mice[J].Mol Ther,2020,28(12):2662-2676.

[37] PONNATH A,DEPREUX F F,JODELKA F M,et al.Rescue of outer hair cells with antisense oligonucleotides in Usher mice is dependent on age of treatment[J].J Assoc Res Otolaryngo,2018,19(1):1-16.

[38] XUE Y,HU X,WANG D,et al.Gene editing in a Myo6 semi-dominant mouse model rescues auditory function[J].Mol Ther,2022,30(1):105-118.

[39] NOH B,RIM J H,GOPALAPPA R,et al.In vivo outer hair cell gene editing ameliorates progressive hearing loss in dominant-negative Kcnq4 murine model[J].Theranostics,2022,12(5):2465-2482.

[40] 吴玉森，王秋菊.USH2综合征型耳聋的基因型与表型特征研究进展[J].听力学及言语疾病杂志，2019,27(5):548-555.

[41] STEMERDINK M,GARCíA-BOHóRQUEZ B,SCHELLENS R,et al.Genetics,pathogenesis and therapeutic developments for Usher syndrome type 2[J].Hum Genet,2022,141(3-4):737-758.

[42] HIGH K A,RONCAROLO M G.Gene therapy[J].N Engl J Med,2019,381(5):455-464.